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THE HUMAN RIBONUCLEOTIDYL TRANSFERASE ZCCHC6 REGULATES
INTERLEUKIN-6 EXPRESSION IN OSTEOARTHRITIS CHONDROCYTES
N. Akhtar, A.R. Arida, T.M. Haqqi. Northeast Ohio Med. Univ., Rootstown,
OH, USA
Purpose: Interleukin-1b (IL-1b) is the major cytokine involved in carti-
lage catabolism in osteoarthritis (OA) and induces the expression of pro-
inﬂammatory cytokine IL-6 and IL-6 is known to induce the expression
of MMP-13 and inhibit type-II collagen expression. Cytoplasmic RNA
nucleotidyl transferases catalyze the addition of nucleotides to the 3’end
of mRNAs. However, the expression or role of RNA nucleotidyl trans-
ferases in regulating cytokine expression in OA is unknown. The aim of
this study was to investigate whether RNA nucleotidyl transferase
ZCCHC6 a recently identiﬁedmemberof the ribonucleotidyl transferases
superfamily, is expressed in OA cartilage, identify the cytokines regu-
lated by ZCCHC6 in chondrocytes, and whether ZCCHC6 is involved in
the regulation of IL-6 expression in OA chondrocytes.
Methods: Chondrocytes were derived by enzymatic digestion of human
cartilage obtained from OA patients (n ¼ 14) undergoing knee joint
replacement. Chondrocyteswere stimulatedwith IL-1b (5ng/ml)or treated
with Actinomycin D (5 mg/ml) or NFlB inhibitor SC514 (75 mM) or JNK
inhibitor (25 mM). Total RNA from grounded cartilage and from chon-
drocytes was puriﬁed using Qiagen RNeasy kit (Qiagen). Reverse tran-
scriptionwasperformedusing theQuantitect Reverse Transcriptionkit and
the ZCCHC6 or IL-6 mRNA was quantiﬁed using TaqMan assays. SiRNA-
mediated depletion of ZCCHC6 in human chondrocytes was used to study
the effect on inﬂammatory cytokine expression using a cytokine array (Ray
Biotech). Protein expression of IL-6 was studied using Western immuno-
blotting and quantiﬁed by ELISA in culture supernatants. Results were
derived using Sigma Plot 12.3 package and p < 0.05 was considered
signiﬁcant.
Results: Higher expression of nucleotidyl transferase ZCCHC6 in the
damaged cartilage compared to unaffected cartilage was observed in all
the samples analyzed. Higher expression of IL-6 (6.0-fold  1.44) in
damaged cartilage compared to smooth cartilage (n¼ 3;p< 0.05) fromOA
patientswas also observed.We further demonstrate that IL-1b stimulation
resulted in a signiﬁcant increase in the expression of the ZCCHC6 mRNA
(11.3-fold1.6) and IL-6mRNA(4956-fold40.6) inhumanchondrocytes
(n¼ 4; p< 0.05)with a corresponding increase inZCCHC6and IL-6 protein
expression. Depletion of ZCCHC6 signiﬁcantly decreased the expression of
IL-6 mRNA (w77-95%) and protein in IL-1b-stimulated chondrocytes.
Importantly, IL-6 mRNAs in IL-1b-stimulated chondrocytes with siRNA-
mediated knockdown of ZCCHC6 expression had shorter poly-A tails
compared to controls (n ¼ 3; p < 0.05). Additionally, OA chondrocytes
transfected with ZCCHC6 siRNA also showed a decrease (w85%) in con-
stitutive IL-6 mRNA expression (n ¼ 3; p < 0.05). Cell supernatants from
control or ZCCHC6siRNA treated chondrocytes stimulatedwith IL-1bwere
analyzed using a cytokine array. A subset of cytokines including IL-6 was
substantially decreasedby lossof ZCCHC6expression (Table-1).Our results
also showed that the IL-1b-induced activation of NF-lB has no role in the
regulation of ZCCHC6 expression in OA chondrocytes and that ZCCHC6
expression was regulated by JNK-MAPKs (n¼ 3; p < 0.05).
Conclusions: Taken together our results for the ﬁrst time demonstrate
that ZCCHC6 is highly expressed in damaged human cartilage of OA
patients. Furthermore, ZCCHC6 regulates IL-6 expression in human
chondrocytes at the post-transcriptional level by inﬂuencing cytokine
mRNA stability. These results identify ZCCHC6 as a possible therapeutic
target for the treatment of OA.Table-1
OA chondrocytes transfected with negative control siRNA or ZCCHC-6 siRNA and
then stimulate
Cytokine Decrease in Expression (% of Control)
IL-6 90%
IL-8 70%
IP-10 98%
RANTES 98%
Figure 1. Bmp2 expression and hypoxia correlate at one-day post fracture
at the periosteum (central panel) and marrow surrounding fracture line
(right panel).221
HYPOXIA IN BONE FRACTURE TRIGGERS BMP2 EXPRESSION AND
ENDOCHONDRAL OSSIFICATION
A.B. Gonzalez-Gil, E. Muinos-Lopez, P. Ripalda-Cemborain,
T. Lopez-Martínez, G. Mora, F. Prosper, F. Granero-Molto. Clínica Univ. de
Navarra, Pamplona, SpainPurpose: Endochondral ossiﬁcation plays an important role during
bone regeneration, failure to initiate it after bone injury results in
atrophic nonunion. The process of endochondral ossiﬁcation is trig-
gered after bone injury through the early expression of BMP2, which
determines mesenchymal progenitors proliferation and further differ-
entiation to the chondrocytic and osteoblastic lineages. However, the
mechanisms that determine BMP2 expression after bone injury are not
yet fully understood. We hypothesized that the hypoxia present at the
injured tissue triggers BMP2 expression. Here we show in a mouse
model of bone regeneration that the hypoxic response and the
expression pattern of Bmp2 are correlated during early phases of the
endochondral ossiﬁcation. In addition we demonstrate in human peri-
osteum that hypoxia is sufﬁcient to induce BMP2 expression.
Methods: To determine Bmp2 expression pattern during endochondral
ossiﬁcation we used transgenic mice engineered to express b-gal-
actosidase under the control of proximal promoter plus 185 kb of the 5’
genomic region of murine Bmp2 (5’Bmp2BAC). Transgenic animals
were subjected to a non-stabilized close fracture of the tibia shaft using
a three point bending device. Dissected tibias were stained with X-Gal
at days 1, 3 and 5 post-fracture to visualize Bmp2 expression. Hypoxia
wasmapped at days 1 and 3 post fracture by pimonidazole HCl injection
and immunodetection of pimonidazole adducts. Human periosteum
explants were obtained after informed consent from patients subjected
to an anterior cruciate ligament reconstruction. Human periosteum
explants were maintained ex vivo for 24 hours under hypoxic con-
ditions (1% O2) or normoxic conditions (21% O2). BMP2 expression was
analyzed by immunoﬂuorescence
Results: One-day post diaphyseal fracture (1 dpf, n ¼ 3) Bmp2
expression signiﬁcantly increased in the bone marrow around the
fracture rim, as well as in the periosteum at the outer line of osteocytes.
Interestingly enough strong hypoxia signaling (adducts) correlated with
Bmp2 expression pattern at the marrow surrounding the fracture line
and in the periosteum (Figure 1). At 3 dpf (n¼ 3), the growing callus and
marrow surrounding the fracture line were still hypoxic, although
Bmp2 expressionwas only present in cells within close contact with the
cortical bone. As expected the hypoxic callus contained BMP2 signaling
(pSmad 1/5/8), proliferating cells (Ki67 positive) as well as being pos-
itive for the marker of chondrogenic differentiation SOX9 a direct target
of BMP2. At 5 dpf we detected only residual expression of Bmp2 at pre-
hypertrophic chondrocytes of the hypoxic callus, and not at the already
vascularized distal areas of the callus that have osteogenic differ-
entiation. The contralateral legs at each time point analyzed as well as
un-fractured tibias presented Bmp2 expression in the vascular struc-
tures and only faint staining of the outer line of osteocytes in close
contact with the periosteum. Nevertheless, these experiments cannot
rule out other factors such as inﬂammation driving Bmp2 expression,
therefore do not discern between causation and correlation between
hypoxia and Bmp2 expression. Hence, we further conﬁrmed the role of
hypoxia as the determinant of BMP2 expression in human periosteum
explants in absence of fracture and inﬂammatory response. For this
purpose, human periosteum explants were subjected to a hypoxia assay
ex vivo. Hypoxia induced accumulation of intracellular BMP2 in peri-
vascular cells of the periosteum (Figure 2) while normoxic periosteum
did not show BMP2 staining
Conclusions: Hypoxia triggers BMP2 expression during endochondral
ossiﬁcation and determines chondrogenic versus osteogenic commit-
ment of mesenchymal progenitors of the periosteum
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S139Figure 2. Hypoxia induces intracellular accumulation of BMP2 in human
periosteum explants.
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LONG NON-CODING RNAS IN OSTEOARTHRITIS AND
CHONDROGENESIS
M.J. Barter y, S. Hyatt z, Y. Xu y, D.A. Young y. yNewcastle Univ., Newcastle
upon Tyne, United Kingdom; zCardiff Univ., Cardiff, United Kingdom
Purpose: Since the advent of the genomic age extensive character-
isation of the transcriptome has indicated the abundance of long non-
coding RNAs (lncRNAs) derived from both intergenic and overlapping
protein-coding gene regions. lncRNAs are expressed in a highly tissue-
speciﬁc manner where they function in various aspects of cell biology.
Although only a fraction have been functionally validated lncRNAs have
emerged as key regulators of gene expression, acting through diverse
mechanisms such as the regulation of epigenetic modiﬁcations and by
acting as scaffolds for protein complex formation at gene loci. The
abundance of lncRNAs in cartilage has yet to be established and
accordingly the potential dysregulation of lncRNA expression in carti-
lage pathology is not yet appreciated. Thus the aims of this study are to
illuminate the chondrocyte non-coding transcriptome, examine alter-
ations during osteoarthritis (OA) and establish functions for lncRNAs in
chondrocyte biology.
Methods: RNA sequencing was performed on human articular cartilage
RNA from patients with end-stage hip OA or neck of femur fracture
(NOF). Sequencing was performed by Illumina Genome Analyzer IIx and
reads aligned to the human genome. Bioconductor packages were used
for normalization and to identify differentially expressed transcripts.
lncRNA expression was validated by real-time RT-PCR. Regulation of
lncRNAs was examined during differentiation of human mesenchymal
stem cells (hMSCs) into chondrocytes, in comparison with adipocytes
and osteoblasts. The role of selected lncRNAs following targeted RNA
interference (RNAi) and overexpression was established in humanchondrocytes and during hMSC chondrogenesis. Cartilage assays such
as the DMB glycosaminoglycan assay and hydroxyproline assay were
used in combinationwith RNA expression and histochemical analysis of
cartilage components.
Results: We have identiﬁed the expression of 5000þ lncRNAs in car-
tilage tissue of which 134 appear differentially expressed in OA
compared with NOF (>2 fold change, Benjamini-Hochberg corrected P
value of < 0.05). In addition we have identiﬁed a number of robustly
expressed novel lncRNAs potentially speciﬁc to the chondrocyte
phenotype. Of particular interest are a group of lncRNAs which sur-
round the master chondrocyte transcription factor SOX9 locus. We
conﬁrmed the presence of these novel lncRNAs in chondrocytes and
examined their expression in a number of additional joint tissues and
during differentiation of hMSCs. Many are speciﬁcally induced during
hMSC chondrogenesis correlating with the induction of SOX9 itself.
Depletion of select lncRNAs by RNAi disrupted hMSC chondrogenesis,
concomitant with reduced cartilage gene expression and matrix
component production, indicating an essential role in chondrocyte
biology.
Conclusions: We have characterised the chondrocyte non-coding
transcriptome and identiﬁed a number of novel lncRNAs. Osteoarthritic
tissue exhibits alterations in lncRNA expression and a number of
robustly expressed chondrocyte lncRNAs have critical roles in chon-
drocyte biology. Our ongoing examination into the mechanisms of
lncRNA function will shed light on chondrocyte gene regulation and
provide a greater understanding of mechanisms which may become
disrupted during the development of osteoarthritis.
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INTERLEUKIN-1B IS ESSENTIAL FOR BLOOD-INDUCED CARTILAGE
DAMAGE IN VITRO
L.F. van Vulpen, G. Roosendaal, R.E. Schutgens, S.C. Mastbergen,
F.P. Lafeber. UMC Utrecht, Utrecht, Netherlands
Purpose: Exposure of joint cartilage to blood can occur after joint
trauma, during or after major joint surgery, or due to hemophilia.
This ultimately leads to joint damage, both by direct effects of
blood on cartilage and via synovial inﬂammation. Cartilage
destruction is considered to result from both cartilage matrix-
degrading proteases as well as cartilage-destructive pro-inﬂamma-
tory cytokines such as IL1b. To unravel the role of IL1b in the
pathogenesis of blood-induced cartilage damage, we investigated
whether direct blocking of IL1b speciﬁcally prevents blood-induced
cartilage damage in vitro.
Methods: Full thickness healthy human articular cartilage explants,
obtained post-mortem, were cultured for 4 days in presence or absence
of 50% v/v whole blood. A recombinant human IL1b monoclonal anti-
body (IL1b mAb) was only added during blood exposure in a concen-
tration of 0, 1, 2, 10, 30, or 100 ng/mL. Cartilage matrix proteoglycan
turnover was determined 12 days later to analyse long-term effects.
Moreover, to investigate the direct effects of IL1b mAb on cartilage,
explants were cultured for 4 days in the presence of 10 ng/mL IL1bmAb
in the absence of blood.
Results: Exposure to blood decreased the proteoglycan-synthesis rate
(-62%) and proteoglycan content (-19%), and increased the proteoglycan
release (þ191%, all p < 0.05). Adding IL1bmAb resulted in a dose-
dependent increase of the proteoglycan synthesis rate leading to nor-
malisation at higher concentrations (see ﬁgure A). Moreover, proteo-
glycan release was statistically signiﬁcantly decreased from a
concentration of 3ng/mL and above (see ﬁgure B). Similar, the proteo-
glycan content increased statistically signiﬁcantly upon addition of the
IL1bmAb (3 ng/mL and above; all p < 0.05). In the absence of blood,
IL1bmAb did not have direct effects on cartilage proteoglycan turnover
(p ¼ 0.51).
Conclusions: This study demonstrates that IL1b is a crucial factor in
the development of blood-induced cartilage damage in vitro. Blocking
this pro-inﬂammatory cytokine with a monoclonal antibody protects
cartilage from the damaging effects of blood exposure. Further
research is warranted to investigate the in vivo capacity of IL1b mAb
in prevention and its position as a treatment of hemophilic
arthropathy.
